Zydus Receives Mexican Regulatory Approval for Cancer Drug – Bhava

Zydus Lifescience announced that the Mexican regulatory authority COFEPRIS (Federal Commission for the Protection against Sanitary Risks) has granted marketing approval for Bhava™, a biosimilar to bevacizumab.

Bhava™ (Bevacizumab) will be available in various strengths of 100 mg/4 ml and 400 mg/16 ml and will be used to treat patients with metastatic colorectal cancer (mCRC), non-squamous non-small cell lung cancer, metastatic breast cancer, glioma, advanced and/or metastatic renal cell carcinoma, and ovarian cancer.

Click here to connect with us on WhatsApp

According to a 2020 WHO report, the most commonly reported cancer cases in Mexico were breast, prostate, colon and thyroid cancers.